Cash/Burn From SEC Filing For Period:
Aurinia is a clinical stage biopharmaceutical company focused on developing and commercializing therapies in disease areas of high unmet medical need. We are currently developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN) and focal segmental glomerularsclerosis (FSGS). Additionally, we are advancing voclosporin ophthalmic solution (VOS), a topical formulation, for the treatment of dry eye syndrome (DES).
Click drug data to see upcoming trial info and prior data
Drug | Disease
Stage | Exp Date
See What The Community Is Saying - Click To See Full Post